News
IBIO
--
0.00%
--
iBio Inc. stock outperforms market on strong trading day
marketwatch.com · 1d ago
Thinking about buying stock in Ion Geophysical, Moneygram International, Akebia Therapeutics, iBio, or Exela Technologies?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for IO, MGI, AKBA, IBIO, and XELA.
PR Newswire - PRF · 07/16 12:30
iBio says successful in preclinical studies for subunit COVID-19 vaccine candidate
MarsBars/E+ via Getty Images IBIO-202, the subunit vaccine candidate developed by iBio (IBIO) against COVID-19 showed a strong and antigen-specific memory T-cell response, the company said. The current commercially available COVID-19
Seekingalpha · 07/16 11:24
iBio's COVID-19 Vaccine Candidate Shows T-Cell Response in Preclinical Studies; Shares Rise Pre-Bell
MT Newswires · 07/16 07:08
BRIEF-Ibio Reports Successful Preclinical Immunization Studies With Next-Gen Nucleocapsid Covid-19 Vaccine Candidate
reuters.com · 07/15 21:14
iBio Reports Successful Preclinical Immunization Studies with Next-Gen Nucleocapsid COVID-19 Vaccine Candidate
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, today announced that preclinical studies of IBIO-202, its subunit vaccine candidate that targets the nucleocapsid protein ("N protein"...
GlobeNewswire · 07/15 21:10
28 Stocks Moving in Friday's Pre-Market Session
Gainers Toughbuilt Industries Inc (NASDAQ: TBLT) shares rose 61% to $1.16 in pre-market trading after the company reported 1H sales through Amazon of $5.48 million, up 118% year over year.
Benzinga · 07/09 11:02
IBio Stock Ticks Higher After Adding Three Cancer Antibody Programs
Benzinga · 07/09 10:10
iBio establishes oncology drug discovery pipeline with three new antibody programs
iBio (IBIO) announces that it is adding three anti-cancer targets to its pipeline of therapeutic candidates.The company also highlighted that it has entered into a research services agreement with FairJourney Biologics
Seekingalpha · 07/08 20:23
iBio Says Establishes Oncology Drug Discovery Pipeline With 3 New Antibody Programs
iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput
Benzinga · 07/08 20:15
iBio Adds Three New Antibody Programs to Pipeline -- Stock Jumps 8% After-Hours
MT Newswires · 07/08 17:16
Will coronavirus eventually become like the seasonal flu?
Morsa Images/DigitalVision via Getty Images Gone are the days when epidemiologists poured over Covid-19 case numbers, as well as new infections and related deaths. As a broad vaccine rollout in
Seekingalpha · 06/20 13:19
Is IBIO Stock A Buy Here?
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of March 31st. The ...
Insider Monkey · 06/19 01:13
Thinking about buying stock in Vaxart, Graybug Vision, Jaguar Health, iBio, or Aptinyx?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VXRT, GRAY, JAGX, IBIO, and APTX.
PR Newswire - PRF · 06/11 13:31
Healthcare names dominate premarket gainers
Amesite (AMST) +61%.GBS (GBS) +40%.Novan (NOVN) +37% on positive results for SB206 in skin infection.Precigen (PGEN) +31% on positive topline results from phase 1b/2a study of AG019 ActoBiotics™.Protagenic Therapeutics (PTIX) +28%.Magnachip Semiconductor
Seekingalpha · 06/11 12:28
BRIEF-iBio Appoints Veteran Biopharmaceutical Executive, Eef Schimmelpennink To Board
reuters.com · 06/09 22:00
iBio adds veteran biopharmaceutical executive to board of directors
iBio (IBIO) announces the appointment of veteran biopharmaceutical executive Evert Schimmelpennink to the company's board of directors, effective immediately.Schimmelpennink has more than 20 years of experience, and has expertise across corporate
Seekingalpha · 06/09 20:44
A plant-based COVID-19 vaccine from a GlaxoSmithKline alliance with Medicago shows strong antibody response
marketwatch.com · 05/18 19:56
iBio Q1 net loss widens as expenses soar year-over-year; shares fall 6%
iBio (IBIO) saw its Q1 net loss increase ~64% to $7.7M ($0.04 per share) year-over-year as the plant-based biologics manufacturing company saw its expenses drastically increase.Revenue for the quarter increased
Seekingalpha · 05/17 14:08
26 Stocks Moving in Monday's Pre-Market Session
Gainers Digital Brands Group, Inc. (NASDAQ: DBGI) shares rose 73.5% to $5.90 in pre-market trading. Digital Brands, on Friday, priced its IPO at $4.15 per share.
Benzinga · 05/17 11:31
Webull provides a variety of real-time IBIO stock news. You can receive the latest news about IBIO through multiple platforms. This information may help you make smarter investment decisions.
About IBIO
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.